Progression of ADP receptor inhibitors antiplatelet drugs

Abstract

Abstract: Antiplatelet therapy has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary sydromes, and it has been successful in reducing mortality and morbidity in the two diseases above-mentioned. Recently, the most commonly used drugs were aspirin and clopidogrel, but some clinical data indicate that the combination of these two drugs doesn't work well for all the patients, which may cause some cardiovascular adverse reactions. Therefore, it's extremely necessary to do some further research on a number of promising new anti-platelet drugs. This article reviews the metabolic and onset characteristic of ADP receptor inhibitors antiplatelet drugs (e.g. clopidogrel, prasugrel, ticagrelor, cangrelor) in the treatment of cardiovascular disease and provide a reference for clinical medicine.

Key words: Antiplatelet drugs, P2Y₁₂ receptor, Prasugrel, Ticagrelor, Cangrelor

CLC Number:

R969

WU Ya-ning, ZHAO Di, LI Ning, CHEN Xi-jing. Progression of ADP receptor inhibitors antiplatelet drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1434-1440.

References

[1] Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ, 2002, 324(7329): 71-86.
[2] Bertrand ME, Rupprecht HJ, Urban P,et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study[J]. Circulation, 2000, 102(6): 624-629.
[3] 张建华, 叶玲丽, 赵玮, 等. 冠心病患者生化阿司匹林抵抗的临床研究[J]. 中国临床药理学与治疗学,2007,12(12): 1437-1438.
[4] Gur S, Kadowitz PJ, Hellstrom WJ. Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview[J]. Curr Pharm Des, 2007, 13(31): 3236-3244.
[5] Knudsen JB, Bastain W, Sefton CM, et al. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics[J]. Xenobiotica, 1992, 22(5): 579-589.
[6] Ha-Duong NT, Dijols S, Macherey AC, et al. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19[J]. Biochemistry,2001, 40(40): 12112-12122.
[7] Caplain H, Donat F, Gaud C, et al. Pharmacokinetics of clopidogrel[J]. Semin Thromb Hemost, 1999, 25(Suppl 2): 25-28.
[8] Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease[J]. Platelets, 2002, 13(7): 407-413.
[9] Sibbing D, Morath T, Stegherr J ,et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost, 2009, 101(4): 714-719 .
[10] Desai NR, Mega JL, Jiang S, et al. Interaction between cigarette smoking and clinical benefit of clopidogrel[J]. J Am Coll Cardiol, 2009, 53(15): 1273-1278 .
[11] Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study[J]. Lancet, 2009, 373(9660): 309-317.
[12] Taubert D, von Beckerath N, Grimberg G,et al. Impact of P-glycoprotein on clopidogrel absorption[J]. Clinical Pharmacology & Therapeutics, 2006, 80(5): 486-501.
[13] Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently[J]. Clin Pharmacol Ther, 2007, 81(5): 735-741.
[14] Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects[J]. Pharmacotherapy, 2008, 28(12): 1483-1494.
[15] Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel[J]. Curr Med Res Opin, 2008, 24(8): 2251-2257.
[16] Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin[J]. Drug Metab Dispos, 2003, 31(1): 53-59.
[17] Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel[J]. J Thromb Haemost, 2007, 5(12): 2429-2436.
[18] Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans[J]. Drug Metab Dispos, 2007, 35(7): 1096-1104.
[19] Farid NA, Jakubowski JA, Payne CD, et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects[J]. Curr Med Res Opin, 2009, 25(8): 1821-1829.
[20] Storey RF, Husted S, Harrington RA, Heptinstall S,Wilcox RG, Peters G et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y₁₂ receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2007, 50(19): 1852-1856.
[21] Gretler DD, Conley PB, Andre P ,et al. "First in human" experience with PRT060128, a new direct-acting, reversible, P2Y₁₂ inhibitor for IV and oral use[J]. J Am Coll Cardiol, 2007, 49 (Suppl2): 326A .
[22] Hechler B, Nonne C, Roh EJ, et al. MRS2500, a potent, selective and stable antagonist of the P2Y₁ receptor, with strong antithrombotic activity in mice[J]. J Pharmacol Exp Ther, 2006,316(2): 556-563.
[23] Guranowski A. Analogs of diadenosine tetraphosphate (Ap4A) [J]. Acta Biochim Pol,2003, 50(4): 947-972.
[24] Horner S, Menke K, Hildebrandt C,et al. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the nanomolar range[J]. Naunyn-Schmiedebergs Arch Pharmacol, 2005, 372(1): 1-13.
[25] Flaumenhaft R,Dilks JR. Discovery-based strategies for studying platelet function[J]. Mini Rev Med Chem, 2008, 8(4): 350-357.